Your morning briefing from CTVNews.ca
 
December 14, 2022

GOOD MORNING

Prime Minister Justin Trudeau talks health-care reform, explaining nuclear fusion and what the latest breakthrough means, and the reason why a drug used to treat Type 2 diabetes is now in short supply in the U.S.

Here's what you need to know to start your day.

Health-care reform

The federal and provincial governments appear deadlocked in their negotiations on the future of health care in Canada, and Prime Minister Justin Trudeau's latest comments suggest he will not be the one to blink first.

What is nuclear fusion?

The announcement of a major breakthrough in fusion research was decades in coming, with scientists for the first time able to engineer a reaction that produced more power than was used to ignite it. But what is nuclear fusion and why is it so difficult?

Short supply

Ozempic, a drug used to treat Type 2 diabetes, has become extremely hard to find in the U.S. after some celebrities and social media influencers touted it as a weight loss solution.

Urban babies

A recently published list ranks 51 Canadian cities on how child-friendly they are, with Quebec City coming out on top as the best to raise children.

New year, new government?

Brace yourselves for an election year in 2023, former NDP leader Tom Mulcair writes in an opinion column for CTVNews.ca

MUST-SEE VIDEO

Twitter CEO Elon Musk was mercilessly booed on stage for 10 minutes by a crowd at a Dave Chappelle show.

ONE MORE THING

Interest in the Canadian men's soccer team has gone up since its World Cup appearance, a new survey finds.

fb tw insta yt yt yt
Subscribe to our other newsletters
Nightly Briefing 5 Things Capital Dispatch

A curated newsletter on the day’s most important news.

The biggest headlines to start your morning.

A twice-weekly update on the latest from Parliament Hill.

You are subscribed to CTV News as [email protected]

You have received this message from CTV News, a Bell Media property.

Bell Media Inc.
9 Channel Nine Ct,
Scarborough, ON M1S 4B5

You can contact us at 1-866-690-6179

Privacy Policy   |   Manage Subscriptions   |   Unsubscribe

© 2022 Bell Media  All rights reserved.
Bell Media